ClinicalTrials.gg
Not yet recruitingNCT07094672Updated Nov 10, 2026

Development of an Opioid Withdrawal Clinical Outcome Assessment

An observational study in Opioid Use Disorder, sponsored by University of Maryland, Baltimore. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Maryland, Baltimore · Observational

How we know

Updated Nov 10, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore — 6 open to participants now, 8 under way, 2 of them phase 3. Opioid-Related Disorders · University of Maryland, Baltimore.

Started
2026
with 2 others
Observational
Only one
of the 16
Registered
14th of 16
by date

Among the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, this one is one of 3 that started in 2026, is the only observational one, and was the 14th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

6 of the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

Withdrawal management strategies are currently the most utilized and ubiquitous intervention for opioid use disorder in the US, yet existing measures of opioid withdrawal lack Food and Drug Administration (FDA) qualification. This project will develop and validate a clinical outcome assessment (COA) for opioid withdrawal,essential for standardizing withdrawal mitigation strategies and establishing best practices. In line with the FDA's drug development tool qualification guidelines, our methodological process will involve conducting focus groups with persons with lived experience of opioid withdrawal for concept elicitation, refining these concepts through cognitive interviews, and conducting construct and longitudinal validations of the new assessment in laboratory settings and across diverse treatment contexts.

Read the detailed description

Participants with opioid use disorder will complete a two sessions in a within-subject study design to compare their responses to withdrawal questions after experiencing naloxone-precipitated withdrawal and following an overnight observation of spontaneous withdrawal. All participants will complete both sessions and the order of sessions will be randomized.

The primary outcome will be cognitive interviews, which will be conducted within 8 hours of each observation period ending to query all possible symptoms associated with the withdrawal experience.

Participants will be offered referrals to aftercare prior to study discharge and transitions to treatment programs will be facilitated whenever possible.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • opioid
  • fentanyl
  • withdrawal
  • naloxone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults with opioid use disorder located or able to access the Baltimore regional area

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Past year opioid use disorder, determined by (a) enrollment in current treatment for opioid use disorder and/or (b) an opioid-positive saliva test.
  • Fluent in English
  • Has experience with opioid withdrawal at least once in the past 30 days

Exclusion criteria

Exclusion Criteria:

  • Unable to provide due to cognitive impairment
  • Being pregnant or breastfeeding
  • History of psychosis or mania as determined by the MINI
  • Exhibiting suicidal behavior in the past 30 days as determined by the C-SSRS
  • Circumstances that could interfere with study participation
  • Previously participated in affiliated Focus Group study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • WIthdrawal assessment_precipitated session

    Assessment of withdrawal following elicitation

  • Withdrawal assessment_spontaneous

    Assessment of withdrawal during a period of opioid abstinence

06

What researchers measure

Primary outcomes

  1. Cognitive interview

    The experience of withdrawal will be probed qualitatively using cognitive interviews to capture all possible symptoms that opioid withdrawal may elicit in an individual

    Time frame: Within 8 hours of completing the withdrawal experience

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Data will be qualitative in nature and collapsed into thematic categories. Individualized data will not be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2027, 9 months later.

Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 9 months is below that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Dec 1, 2026
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Oct 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07094672
Responsible party
Kelly Dunn (Director, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore) — Principal investigator
First posted
Jul 30, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Kelly E Dunn, Ph.D., MBA
Contact
kelly.dunn@som.umaryland.edu
410 ext. 202-963-1952

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion